Loading...
•
Mar 31, 2020
ANI Pharmaceuticals Q1 2020 Earnings Report
ANI Pharmaceuticals' Q1 2020 results were reported, including the integration of Amerigen Pharmaceuticals, Ltd. portfolio and the appointment of Patrick D. Walsh as interim CEO.
Key Takeaways
ANI Pharmaceuticals reported net revenues and non-GAAP earnings that met management's expectations, launched five generic products, and integrated the Amerigen Pharmaceuticals, Ltd. portfolio. However, the company experienced a net loss and decreased earnings per share compared to the prior year period and suspended its 2020 financial guidance due to COVID-19 uncertainties.
Integrated Amerigen Pharmaceuticals, Ltd. portfolio.
Launched five generic products, increasing the total commercialized product line to 60 product families.
Appointed Patrick D. Walsh as interim President and CEO.
Suspended guidance for 2020 due to COVID-19 uncertainties.
ANI Pharmaceuticals
ANI Pharmaceuticals
ANI Pharmaceuticals Revenue by Segment
Revenue by Segment
Brands Revenue
CapyFin.comGeneric Pharmaceutical Products Revenue
CapyFin.comRoyalties and Other Revenue
CapyFin.com Forward Guidance
Due to inherent uncertainties regarding the duration and impact of the coronavirus (COVID-19) pandemic, ANI is suspending its previously announced 2020 financial guidance.
Revenue & Expenses
Visualization of income flow from segment revenue to net income